150
Participants
Start Date
February 3, 2015
Primary Completion Date
April 30, 2019
Study Completion Date
April 28, 2022
Talimogene Laherparepvec
Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
Immediate surgical resection of melanoma lesion(s)
Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
Research Site, North Sydney
Research Site, Heidelberg
Research Site, Woodville South
Research Site, Chur
Research Site, Zurich
Research Site, New York
Research Site, New York
Research Site, Athens
Research Site, Marseille
Research Site, Philadelphia
Research Site, Dijon
Research Site, Chapel Hill
Research Site, Madrid
Research Site, Málaga
Research Site, Pamplona
Research Site, Toulouse
Research Site, Daytona Beach
Research Site, Gainesville
Research Site, Tampa
Research Site, Birmingham
Research Site, Memphis
Research Site, Louisville
Research Site, Columbus
Research Site, Omaha
Research Site, Pierre-Bénite
Research Site, Heraklion - Crete
Research Site, Paris
Research Site, Dallas
Research Site, Dallas
Research Site, Houston
Research Site, Salt Lake City
Research Site, Santa Monica
Research Site, Duarte
Research Site, Orange
Research Site, San Francisco
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Worcester
Research Site, New Brunswick
Research Site, Florianópolis
Research Site, Barretos
Research Site, Rio de Janeiro
Research Site, Poznan
Research Site, Warsaw
Research Site, Wroclaw
Lead Sponsor
Amgen
INDUSTRY